SCHEMBL298889

SCHEMBL298889

O=C(c1cccc(NS(=O)(=O)c2ccc(OC(F)(F)F)cc2)c1)c1c[nH]c2ncc(Cl)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR9 P51686 5/20 0.50
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
TCF4 P15884 1/20 0.43
CTNNB1 P35222 1/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 1/20 0.43
BRAF P15056 4/20 0.43
BTK Q06187 1/20 0.42
ITGA1 P56199 1/20 0.42
CYP3A4 P08684 1/20 0.41
BMPR1B O00238 1/20 0.41
PLK4 O00444 1/20 0.41
PIR O00625 1/20 0.41
AURKA O14965 1/20 0.41
DCLK1 O15075 1/20 0.41
EPHB6 O15197 1/20 0.41
RIPK2 O43353 1/20 0.41
STK16 O75716 1/20 0.41
OXSR1 O95747 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL298399 0.92 BRAF (0.45) CCR9CYP2C9CYP2C19BRAFBTK
SCHEMBL298707 0.89 CCR9 (0.46) CCR9CYP2C9CYP2C19BRAFBTK
SCHEMBL298085 0.88 CYP19A1 (0.49) CCR9CYP2C9CYP2C19BRAFBTK
SCHEMBL298104 0.88 CYP2C9 (0.53) CYP2C9CYP2C19BRAFBTKITGA1
SCHEMBL298193 0.87 CYP2C9 (0.47) CCR9CYP2C9CYP2C19BRAFCYP3A4
SCHEMBL297843 0.84 GAA (0.48) CYP2C9CYP2C19BRAFCYP3A4KIT
SCHEMBL3710534 0.84 CYP3A4 (0.57) CYP2C9CYP2C19BRAFBTKCYP3A4
SCHEMBL3709466 0.84 PGR (0.50) CYP2C9CYP2C19BRAFBTKCYP3A4
SCHEMBL299321 0.84 PAK1 (0.45) TCF4CTNNB1ABL1CSF1RKIT
SCHEMBL298324 0.82 CYP3A4 (0.47) CCR9CYP2C9CYP2C19BRAFCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. 2012-05-17 US disclosed
EP-2427433-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS Plexxikon, Inc. (US) 2012-03-14 EP disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed
WO-2010129570-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS PLEXXIKON, INC. (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122860-A1 SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS BRAF, RAF1, ARAF CCR9 3946/4885ROCK2 1679/4885ROCK1 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.